紫杉醇联合卡培他滨治疗晚期胃癌的疗效及安全性

Efficacy and Safety of Paclitaxel Plus Capecitabine for Advanced Gastric Cancer

目的探讨紫杉醇联合卡培他滨治疗晚期胃癌的疗效及安全性。方法选取50例晚期胃癌患者,分为实验组25例,对照组25例。实验组采用紫杉醇联合卡培他滨治疗,对照组仅采用卡培他滨治疗,治疗时间为4周期,分析紫杉醇联合卡培他滨治疗晚期胃癌的疗效及安全性。结果实验组完全缓解2例,部分缓解13例,缓解率60%;对照组完全缓解1例,部分缓解12例,缓解率52%。2组缓解率比较,差异有统计学意义,P<0.05。实验组无恶性发展21例,改善率84%;对照组无恶性发展16例,改善率64%。2组改善率对比,差异有统计学意义(P<0.05)。实验组和对照组患者在治疗前后的血常规、肝肾功能、血糖、血脂及其他可能由用药引起的不良反应方面,差异无统计学意义,P>0.05。结论紫杉醇联合卡培他滨对胃癌晚期患者病症的改善以及控制有良好的疗效,并且在临床上不会引起患者相关的其它严重不良反应,可以作为治疗晚期胃癌患者的治疗方法。

Objective To study the efficacy and safety of paclitaxel plus capecitabine for advanced gastric cancer. Methods 50 cases of patients with advanced gastric cancer were divided into the experimental group and the control group, each with 25 cases. The experimental group received pac｜itaxal plus capecitabine treatment,the control group using eapecitabine treatment, treatment time was 4 cycles, the efficacy and safety of paclitaxel plus capecitabine for advanced gastric cancer were analyzed. Results In the experimental group, there had 2 cases of complete remission, partial remission in 13 cases, remission rate was 60%, in the control group, there had 25 cases of patients, 1 case of complete remission, partial remission in 12 cases, remission rate was 52%, remission rate between the 2 groups had statistically significant difference, P 〈 0.05 ; In the experimental group ,21 cases had non-malignant development,improvement rate was 84% ,in the control group, 16 cases had non-malignant de- velopment,improvement rate was 64% , the difference was statistically significant （ P 〈 0.05 ） ; liver and kidney function, blood glucose,hpids and other adverse symptoms may be caused by medication before and after treatment between the 2 groups had no statistically significant diffcrence,P 〉 0.05. Conclusion Paclitaxel plus capecitabine for advanced gastric cancer is .effective, without cause other serious adverse symptoms in the clinic, it can be used as treatment for patients with advanced gastric cancer.